Quinoline Or Isoquinoline (including Hydrogenated) Patents (Class 544/363)
-
Publication number: 20100143917Abstract: Chemical compounds having a high selectivity for double stranded DNA over RNA and single stranded DNA are disclosed. The chemical compounds are stains that become fluorescent upon illumination and interaction with double stranded DNA, but exhibit reduced or no fluorescence in the absence of double stranded DNA. The compounds can be used in a variety of biological applications to qualitatively or quantitatively assay DNA, even in the presence of RNA.Type: ApplicationFiled: October 5, 2009Publication date: June 10, 2010Applicant: LIFE TECHNOLOGIES CORPORATIONInventors: Jolene A. BRADFORD, Ching-Ying CHEUNG, Shih-Jung HUANG, Patrick R. PINSON, Stephen T. YUE
-
Patent number: 7732600Abstract: Disclosed are methods for the preparation of compounds of formula (I): wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.Type: GrantFiled: August 13, 2009Date of Patent: June 8, 2010Assignee: Glaxo Group LimitedInventors: Markus Bergauer, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok Keong Vong, Simon Edward Ward
-
Publication number: 20100137329Abstract: The invention relates to a compound having general formula (I): Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.Type: ApplicationFiled: February 8, 2010Publication date: June 3, 2010Applicant: SANOFI-EVENTISInventors: Ahmed ABOUABDELLAH, Antonio Almario Garcia, Christian Hoornaert, Adrien Tak Li
-
Publication number: 20100135999Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: October 5, 2009Publication date: June 3, 2010Applicant: SANOFI-AVENTISInventors: Marc Nazaré, Gernot ZECH, Melitta JUST, Tilo WEISS, Gerhard HESSLER, Joerg Czech
-
Publication number: 20100130469Abstract: The present invention relates to novel organic compounds comprising a naphthyridine which may be mediators of a selective subset of kinases belonging to the AGC kinase family, such as for example PKC, PKD, PKN-1/2, CDK-9, MRCK-beat, PASK, PRKX, ROCK-I/II or mediators of other kinases, the selectivity of which would be depending on the structural variation thereof.Type: ApplicationFiled: April 4, 2008Publication date: May 27, 2010Inventors: Maurice van Eis, Walter Schuler, Anette Von Matt, Nicolas Soldermann, Lauren G. Monovich, Christoph Gaul
-
Publication number: 20100130744Abstract: The present invention relates to an improved process for the preparation of 7-[4-[4-(2,3-dichlorophenyl)-1-piper-azinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone of Formula (I).Type: ApplicationFiled: May 29, 2008Publication date: May 27, 2010Inventors: Mahesh Nagarimadugu, Vipin Kumar Kaushik, Ramesh Dandala, Sivakumaran Meenakshisunderam
-
Publication number: 20100120769Abstract: The present invention relates to compounds of formula I wherein s, R1a and R1 to R3 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.Type: ApplicationFiled: January 20, 2010Publication date: May 13, 2010Inventors: Matthias Nettekoven, Jean-Marc ` Plancher, Olivier Roche, Tadakatsu Takahashi, Sven Taylor
-
Patent number: 7714129Abstract: Provided is a method of preparing aripiprazole anhydrous Form II from aripiprazole.Type: GrantFiled: September 29, 2006Date of Patent: May 11, 2010Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Hagit Eisen-Nevo, Zhanna Pavlov
-
Publication number: 20100113784Abstract: The present invention relates the process for preparation of stable polymorph of aripiprazole and in particular the present invention is related to an improved process for the preparation of crystalline anhydrous aripiprazole and its hydrochloride salt.Type: ApplicationFiled: September 24, 2007Publication date: May 6, 2010Inventors: Niraj Shyamlal Shah, Shriprakash Dhar Dwivedi, Kishorkumar Maneklal Vinchhi, Sathya Varahala Raju Nadimpally
-
Publication number: 20100113473Abstract: An aryl amide compound of Formula (I): or a pharmaceutically acceptable form thereof is disclosed. The compound is an ACC inhibitor and therefore useful in treating an ACC-mediated condition.Type: ApplicationFiled: October 20, 2009Publication date: May 6, 2010Inventors: Mark R. Player, Jian Liu
-
Patent number: 7705146Abstract: The invention relates to compounds of formula (I) wherein R?, R2, R3, R4, R5, R6, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I).Type: GrantFiled: June 22, 2005Date of Patent: April 27, 2010Assignee: Boehringer Ingelheim International GmbHInventors: Murray D. Bailey, Punit Bhardwaj, Pasquale Forgione, Elise Ghiro, Nathalie Goudreau, Teddy Halmos, Montse Llinas-Brunet, Marc-Andre Poupart, Jean Rancourt
-
Publication number: 20100099676Abstract: A compound represented by the general formula (I): wherein R1 is wherein R26 and R28 are each independently lower alkyloxy and the like; n1 is an integer of 0 to 3; Z is a optionally substituted C1-C5 alkynylene which may be interrupted with a substituent selected from Substituent group a and the like; A is a group represented by the formula: wherein R6 and R7 are each independently lower alkyl and the like; m and n are each independently 0, 1, or 2; R2 is a hydrogen atom and the like; R3 is optionally substituted lower alkyl and the like; R4 is a hydrogen atom; or R3 and R4 may be taken together with an adjacent carbon atom to from a ring; R5 is hydroxyl and the like, or an optically active isomer, a pharmaceutically acceptable salt or a solvate thereof.Type: ApplicationFiled: October 31, 2007Publication date: April 22, 2010Applicant: SHIONOGI & CO., LTD.Inventors: Takeshi Endoh, Yasuhiko Fujii, Eiichi Kojima, Genta Tadano, Naoko Yamaguchi, Yo Adachi, Sachie Tagashira, Yuki Tachibana, Naohiro Onodera
-
Publication number: 20100099674Abstract: A means for decreasing bacterial virulence in a mammal including man or in a plant by inhibition of the Type III secretion system at concentrations that do not prevent or substantially reduce bacterial growth comprises an N-substituted 7-quinolylmethyl amine, in particular one that is further substituted in 5- and 8-position on the quinoline ring. A corresponding therapeutic method and a pharmaceutical composition are also disclosed.Type: ApplicationFiled: March 18, 2008Publication date: April 22, 2010Applicant: Innate Pharmaceuticals ABInventor: Mikael Elofsson
-
Publication number: 20100099665Abstract: The present invention relates to isoquinolinone derivatives of formula (I): wherein are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.Type: ApplicationFiled: October 1, 2009Publication date: April 22, 2010Applicant: AstraZeneca ABInventors: Stephen John BROUGH, Timothy Jon Luker, Bryan Glyn Roberts, Stephen Anthony St-Gallay
-
Publication number: 20100099659Abstract: This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.Type: ApplicationFiled: December 11, 2009Publication date: April 22, 2010Inventors: Joshua Kennedy-Smith, Rama K. Kondru, Bradley E. Loe, Yan Lou, Joel Mclntosh, Timothy D. Owens, Michael Soth, Zachary Kevin Sweeney, Joshua Paul Gergely Taygerly
-
Publication number: 20100094005Abstract: The invention relates to a fluorinated derivate of quinolin-2(1H)-one (I), to a method for preparing the same, and to the use thereof as an intermediate in the synthesis of 7-fluoro-2-oxo-4-[2-[4-[thieno[3,2-c]pyridine-4-yl)piperazin-1-yl]ethyl]-1,2-dihydro-quinolin-1-acetamide. The invention also relates to the pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 12, 2009Publication date: April 15, 2010Applicant: SANOFI-AVENTISInventors: Didier LEGROUX, Veronique MORAGUES, Jose RUIZ-MONTES, Laurent SALLE
-
Publication number: 20100093726Abstract: The present invention relates to clotrimazole/quinoline hybrids useful as active ingredients of anti-malaria drugs. The compounds show a remarkable in vitro biological activity especially against the chloroquine-resistant Plasmodium falciparum strains and in vivo activity against P. berghei.Type: ApplicationFiled: February 18, 2008Publication date: April 15, 2010Applicant: Giuseppe CAMPIANIInventors: Giuseppe Campiani, Sandra Gemma, Caterina Fattorusso, Gagan Kukreja, Bhupendra Prasad Joshi, Stefania Butini, Marco Persico, Salvator Sanna Coccone, Matteo Bernetti
-
Publication number: 20100087445Abstract: This invention provides novel aryl piperazine derivatives represented by Formula (I) having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, 5HT1A and 5-HT2A receptor subtypes, and in particular useful for the treatment of neuropsychiatric disorders, incl. schizophrenia.Type: ApplicationFiled: October 12, 2007Publication date: April 8, 2010Applicant: Universita degli Studi di SienaInventors: Giuseppe Campiani, Stefania Butini, Caterina Fattorusso, Silvia Franceschini, Irene Zia Thale, Karin Sandager Nielsen, Jørgen Scheel-Krüeger, Lars Siim Madsen
-
Patent number: 7691862Abstract: The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.Type: GrantFiled: July 2, 2007Date of Patent: April 6, 2010Assignee: Regena Therapeutics LCInventors: Frank Wingrove, Rex McKee
-
Publication number: 20100081646Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.Type: ApplicationFiled: August 19, 2009Publication date: April 1, 2010Applicant: KALYPSYS, INC.Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
-
Patent number: 7687503Abstract: The invention relates to a compound having general formula (I): Wherein m, R1 and R2 are as defined herein. The invention also relates to the use of the compound in therapeutics. More specifically, the compounds of the invention are inhibitors of the FAAH enzyme, and therefore, can be used for the treatment of various disorders associated with FAAH enzyme, which include in a non-limiting manner, pain, eating disorders, neurological and psychiatric pathologies, among other disorders.Type: GrantFiled: June 22, 2006Date of Patent: March 30, 2010Assignee: Sanofi-AventisInventors: Ahmed Abouabdellah, Antonio Almario Garcia, Christian Hoornaert, Adrien Tak Li
-
Patent number: 7683066Abstract: The present invention relates to compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.Type: GrantFiled: May 15, 2006Date of Patent: March 23, 2010Assignee: Vertex Pharmaceuticals IncorporatedInventors: Andreas Termin, Dean Wilson, Pramod Joshi
-
Publication number: 20100069399Abstract: The present invention relates to new arylpiperazine modulators of D2 receptors, 5-HT1A receptors, and/or 5-HT2A receptors, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: February 27, 2009Publication date: March 18, 2010Applicant: AUSPEX PHARMACEUTICAL, INC.Inventors: Thomas G. Gant, Sepehr Sarshar, Chengzhi Zhang
-
Patent number: 7678798Abstract: The present invention relates to compounds of Formula I: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as inflammatory diseases, immune diseases and viral infections.Type: GrantFiled: April 12, 2005Date of Patent: March 16, 2010Assignee: Incyte CorporationInventors: Chu-Biao Xue, Ganfeng Cao, Taisheng Huang, Lihua Chen, Ke Zhang, Anlai Wang, David Meloni, Rajan Anand, Joseph Glenn, Brian W. Metcalf
-
Publication number: 20100063061Abstract: The present invention relates to novel substituted quinoline derivatives according to the general formula (Ia) or formula (Ib): including any stereochemically isomeric form thereof, a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.Type: ApplicationFiled: December 4, 2007Publication date: March 11, 2010Inventors: Jérôme Emile Georges Guillemont, Magali Madeleine Simone Motte, Koenraad Jozef Lodewijk Marcel Andries, Anil Koul
-
Publication number: 20100063026Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a pharmaceutically acceptable salt thereof, a N-oxide form thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.Type: ApplicationFiled: December 4, 2007Publication date: March 11, 2010Inventors: Jérôme Emile Georges Guillemont, Ismet Dorange, David Francis Alain Lançois, José Manuel Villalgordo-Soto, Yvan René Ferdinand, Magali Madeleine Simone Motte, Koenraad Jozef Lodewijk Marcel Andries, Anil Koul
-
Publication number: 20100063279Abstract: The present invention relates to a method for producing a quinolone compound having high antibacterial activity and high safety, at high yield and in a simple manner. A quinolonecarboxylic acid derivative (1) of interest is produced through a one-pot manner by reacting a compound (2) with a salt of a cyclic amine (3) and with a boron derivative in a solvent in the presence of a base.Type: ApplicationFiled: September 30, 2009Publication date: March 11, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Koji SATO, Kenji Sakuratani
-
Publication number: 20100056518Abstract: The invention relates to 6-substituted isoquinolone derivatives of the formula (I) useful for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, and compositions containing such compounds.Type: ApplicationFiled: June 18, 2009Publication date: March 4, 2010Applicant: SANOFI-AVENTISInventors: Oliver PLETTENBURG, Armin HOFMEISTER, Katrin LORENZ, Joachim BRENDEL, Matthias Löhn, John Weston
-
Patent number: 7671056Abstract: The present invention relates to novel piperazine-piperidine compounds. The compounds are useful as 5-HT1A binding agents, particularly as 5-HT1A receptor antagonists and agonists. These compounds are useful in treating central nervous system disorders, such as cognition disorders, anxiety disorders, depression and sexual dysfunction. The invention relates to compounds and pharmaceutically acceptable salts of formula (I?): wherein R1-R16, Ra, Rb, and n are set forth in the specification. The invention also relates to pharmaceutical compositions comprising compounds and pharmaceutically acceptable salts of formula (I?).Type: GrantFiled: June 9, 2006Date of Patent: March 2, 2010Assignee: Wyeth LLCInventors: Magda Asselin, George Theodore Grosu, Annmarie Louise Sabb, Wayne Everett Childers, Lisa Marie Havran, Zhongqi Shen, James Jacob Bicksler, Dan Chaekoo Chong
-
Publication number: 20100048585Abstract: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, a tautomeric form thereof or a N-oxide form thereof, wherein R1 is hydrogen, halo, haloalkyl, cyano, hydroxy, Ar, Het, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkylthioalkyl, Ar-alkyl or di(Ar)alkyl; p is 1, 2, 3 or 4; R2 is hydrogen, hydroxy, mercapto, alkyloxy, alkyloxyalkyloxy, alkylthio, mono or di(alkyl)amino or a radical of formula; R3 is alkyl, Ar, Ar-alkyl, Het or Het-alkyl; q is 1, 2 or 3; R4 and R5 are hydrogen, alkyl or benzyl; or R4 and R5 together and including the N to which they are attached may form a ring; R6 is hydrogen, halo, haloalkyl, hydroxy, Ar, alkyl, alkyloxy, alkylthio, alkyloxyalkyl, alkythioalkyl, Ar-alkyl or di(Ar)alkyl; or two vicinal R6 radicaType: ApplicationFiled: June 26, 2006Publication date: February 25, 2010Inventors: Koenraad Jozef Lodewijk Marcel Andries, Anil Koul, Jérôme Emile Georges Guilliemont, David Francis Alain Lancois, Magali Madeleine Simone Motte, Ismet Dorange, Leo Jacobus Jozef Backx, Lieven Meerpoel
-
Publication number: 20100048566Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.Type: ApplicationFiled: December 4, 2007Publication date: February 25, 2010Applicant: JANSSEN PHARMACEUTICA N,V,Inventors: Jérôme Emile Georges Guillemont, David Francis Alain Lancois, Ismet Dorange, Koenraad Josef Lodewijk Andries, Anil Koul
-
Patent number: 7666873Abstract: The present invention relates to a novel N-phenyl-(2R,5S)dimethylpiperazine derivatives useful as antiandrogenic agent which exhibits a sufficient prostate gland reducing effect as compared with conventional compounds and are excellent in oral activity. The compound of the present application is useful in preventing or treating prostate cancer, benign prostatic hyperplasia, and the like. The present invention also provides a novel intermediate useful in producing the compound of the present invention.Type: GrantFiled: September 26, 2007Date of Patent: February 23, 2010Assignee: Astellas Pharma Inc.Inventors: Nobuaki Taniguchi, Masakazu Imamura, Masahiko Hayakawa, Kenichi Kawaguchi, Takenori Kimura, Isao Kinoyama, Hiroyuki Kaizawa, Minoru Okada, Takashi Furutani
-
Patent number: 7667037Abstract: Provided are processes for preparing ziprasidone from CEI and BIPT.Type: GrantFiled: October 25, 2004Date of Patent: February 23, 2010Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Gideon Pilarsky, Natalia Shenkar, Marioara Mendelovici, Tamar Nidam, Anna Balanov
-
Publication number: 20100029634Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof.Type: ApplicationFiled: March 30, 2009Publication date: February 4, 2010Inventors: Michael P. Clark, Florence F. Wagner, Brandon C. Doroh, Tricia L. Johnson, Yesim Altas Tahirovic, Lawrence Wilson, John M. Wiseman, Jason W. Skudlarek, Mark A. Lockwood, Michael G. Natchus
-
Publication number: 20100029938Abstract: It comprises a process for the preparation of levofloxacin based on a cyclisation reaction of a compound of formula (IV), which has the alcohol group protected, followed by a deprotection reaction and the conversion of the compound obtained to levofloxacin by a process comprising a hydrolysis reaction and a second cyclisation reaction. It also comprises new intermediates compounds.Type: ApplicationFiled: December 22, 2007Publication date: February 4, 2010Applicant: FARMAPROJECTS, S. A.Inventors: Salvador Puig Torres, Jordi Bessa Bellmunt
-
Publication number: 20100029679Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or Formula (Ib): including any stereochemically isomeric form thereof, a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the treatment of a bacterial infection and a process for preparing the claimed compounds.Type: ApplicationFiled: December 4, 2007Publication date: February 4, 2010Inventors: Jérôme Emile Georges Guillemont, Ismet Dorange, Magali Madeleine Simone Motte, Koenraad Jozef Lodewijk Marcel, Anil Koul
-
Patent number: 7655798Abstract: Crystalline aripiprazole Type II can be formed without solid state heat treatment. Instead a liquid is used such as in crystallizing from a solvent, especially 2-propanol, dimethyl sulfoxide, or a combination thereof with ethyl acetate, or in a solvent mediated solid-solid transformation, typically in ethyl acetate.Type: GrantFiled: March 17, 2006Date of Patent: February 2, 2010Assignee: Synthon BVInventors: Gerrit J. B. Ettema, Raymond J. H. Westheim, Faysal Kalmoua
-
Publication number: 20100022515Abstract: The invention provides compounds, pharmaceutical compositions comprising compound of following formula (I), and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119 (G protein-coupled receptor 119) such as obesity, diabetes and hyperlipidemia.Type: ApplicationFiled: January 22, 2008Publication date: January 28, 2010Applicant: IRM LLCInventors: Phillip B. Alper, Mihai D. Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Pierre-Yves Michellys, Truc Ngoc Nguyen, Lucas Westcott-Baker, Baogen Wu
-
Patent number: 7652014Abstract: The present invention provides compounds of formula (I), their use as PARP inhibitors as well as pharmaceutical compositions comprising said compounds of formula (I) wherein n, s, R1, R2, R3, Q, X and Y have defined meanings.Type: GrantFiled: November 18, 2004Date of Patent: January 26, 2010Assignee: Janssen PharmaceuticaInventors: Dominique Jean-Pierre Mabire, Jacobus Alphonsus Josephus Van Dun, Maria Victorina Francisca Somers, Walter Boudewijn Leopold Wouters
-
Publication number: 20100016282Abstract: The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.Type: ApplicationFiled: July 8, 2009Publication date: January 21, 2010Inventors: Johannes Aebi, Alfred Binggeli, Luke Green, Guido Hartmann, Hans P. Maerki, Patrizio Mattei, Fabienne Ricklin, Olivier Roche
-
Publication number: 20100009980Abstract: A subject of the invention is the compounds of formula (I): wherein R1, R2, R3, R?3, R4, R?4, R5, R6 and R7 are as described in the application, in the form of enantiomers or mixtures, as well as their salts with acids and bases, their preparation and their application as anti-bacterials, in both human and veterinary medicine.Type: ApplicationFiled: June 23, 2009Publication date: January 14, 2010Applicant: Vetoquinol SAInventors: Sandrine Ropp, Christophe Morice, Bruno Giethlen, Paola Ciapetti, Florence Chery-Mozziconacci, Camille G. Wermuth, Francoise Leblanc, Marc Schneider
-
Publication number: 20100009979Abstract: The invention relates to the use of quaternary ammonium compounds for preventing precipitations of fluoroquinolones from their solutions and to stable, tolerated pharmaceuticals which are particularly suitable for parenteral use and which contain, in dissolved form, a fluoroquinolone and a quaternary ammonium compound.Type: ApplicationFiled: February 23, 2007Publication date: January 14, 2010Applicant: BAYER ANIMAL HEALTH GMBHInventors: Iris Heep, Kristine Fraatz, Hans-Juergen Hamann, Markus Edingloh
-
Patent number: 7645759Abstract: Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor are disclosed. The compounds have the general formula (I) in which R is hydrogen or methyl; W is a single bond or an oxygen atom; n=3; X is hydrogen or a —NR1R2 amino group in which R1 and R2 can be independently hydrogen or a group which is methyl, ethyl, n-propyl, or isopropyl; Y is a —NR3R4R5 quaternary ammonium group in which R3, R4, R5 can be independently a group which is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, or n-pentyl; and the enantiomers and enantiomeric mixtures thereof. Pharmaceutical compositions containing these compounds and methods of using the compounds to treat patients having conditions, disorders or diseases involving activation of bradykinin B2 receptors are also disclosed.Type: GrantFiled: April 10, 2007Date of Patent: January 12, 2010Assignee: Istituto Luso Farmaco D'Italia S.p.A.Inventors: Patrizia Felicetti, Christopher Ingo Fincham, Alessandro Giolitti, Carlo Alberto Maggi, Laura Quartara, Cristina Rossi
-
Publication number: 20100004452Abstract: Disclosed are compounds of formula (I) wherein R1 is C1-6alkyl, halo or haloC1-6alkyl; R2 is hydrogen or C1-6alkyl; is a single or double bond; each R3 and R4, which may be the same or different, are hydrogen, C1-6alkyl or haloC1-6alkyl; wherein i) when is a double bond p and q are 1, and ii) when is a single bond, p and q are 2, and one of R3 and one of R4, together with their interconnecting atoms, forms a cyclopropane ring which may be substituted by one or two halo or methyl groups, which groups may be the same or different; X is CH or N; when present each R5, which may be the same or different, is C1-6alkyl or halo; or two R5 groups may join to form a bridge, which bridge contains one or two atoms; n is 0, 1, 2 or 3; when present each R6 which may be the same or different, is C1-6alkyl or halo; and m is 0, 1, 2 or 3.Type: ApplicationFiled: September 24, 2007Publication date: January 7, 2010Inventors: Barbara Bertani, Steven Mark Bromidge, Massimo Gianotti, Alessandra Pasquarello, Valeria Zucchelli
-
Publication number: 20100004261Abstract: Certain piperazinyl and piperidinyl urea compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: ApplicationFiled: September 11, 2009Publication date: January 7, 2010Inventors: Richard Apodaca, J. Guy Breitenbucher, Kanaka Pattabiraman, Mak Seierstad, Wei Xiao
-
Patent number: 7642353Abstract: Crystalline aripiprazole Form B can be formed by crystallizing from a solvent selected from 1-propanol, 2-propanol, 1-butanol, ethyl acetate, acetonitrile or a combination thereof.Type: GrantFiled: November 18, 2005Date of Patent: January 5, 2010Assignee: Synthon BVInventors: Gerrit Jan Ettema, Raymond Westheim, Faysal Kalmoua
-
Publication number: 20090318684Abstract: The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are compounds that inhibit Rho-protein associated kinase function. Compounds of the invention include piperazinyl pyridines, piperazinylmethyl pyridines, piperazinyl ureas and carbamates, piperazinyl pyridines and quinoilines (including isoquinliones) as well as piperazinyl (including piperazinylmethyl) pyridines and quinolines (including isoquinolines). Compounds of the invention disrupt Rho-kinase activation and function and significantly inhibit tumor cell growth and induce tumor cell death.Type: ApplicationFiled: June 22, 2009Publication date: December 24, 2009Applicants: UNIVERSITY OF SOUTH FLORIDA, YALE UNIVERSITYInventors: Said M. Sebti, Andrew D. Hamilton
-
Publication number: 20090312546Abstract: Disclosed are methods for the preparation of compounds of formula (I): wherein R1, m, X, R2, n, W, p, Y, Z, R3, R4, R5 and q have the meanings as defined in the description.Type: ApplicationFiled: August 13, 2009Publication date: December 17, 2009Inventors: Markus BERGAUER, Barbara Bertani, Matteo Biagetti, Steven Mark Bromidge, Alessandro Falchi, Colin Philip Leslie, Giancarlo Merlo, Domenica Antonia Pizzi, Marilisa Rinaldi, Luigi Piero Stasi, Jessica Tibasco, Antonio Kuok, Keong Vong, Simon Edward Ward
-
Publication number: 20090306041Abstract: This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: wherein, variables R, X, Y1, Y2, Y3, Y4, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.Type: ApplicationFiled: February 5, 2009Publication date: December 10, 2009Inventors: Nolan James Dewdney, Joshua Kennedy-Smith, Rama K. Kondru, Bradley E. Loc, Yan Lou, Joel McIntosh, Timothy D. Owens, Michael Soth, Zachary Kevin Sweeney, Joshua Paul Gergely Taygerly
-
Patent number: RE41149Abstract: N1-(1,2-cis-2-halogenocyclopropyl)-substituted pyridonecarboxylic acid derivatives represented by the following formula (I) the terms of which are defined in the specification and the salts thereof are disclosed: These compounds have patent antibacterial activities against a wide variety of infectious bacteria and are useful as antibacterial agents by oral or parenteral administration.Type: GrantFiled: June 3, 2004Date of Patent: February 23, 2010Assignee: Daiichi Sankyo Company, LimitedInventors: Isao Hayakawa, Youichi Kimura